Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elexacaftor/Tezacaftor/Ivacaftor in CF with F/G or F/RF Genotypes
NCT04058353Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of elexacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Aug 2019; status: completed.
02
Drugs
elexacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04058353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04058353.